OTCMKTS:GNBT - Generex Biotechnology Stock Price, Price Target & More

$3.00 +0.21 (+7.53 %)
(As of 04/26/2018 08:55 AM ET)
Previous Close$2.79
Today's Range$2.80 - $3.00
52-Week Range$2.16 - $6.00
Volume700 shs
Average Volume2,040 shs
Market Capitalization$3.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1

About Generex Biotechnology (OTCMKTS:GNBT)

Generex Biotechnology Corporation, through its subsidiary, Hema Diagnostic Systems, LLC, focuses on the development, manufacture, and distribution of in-vitro medical diagnostics for infectious diseases in Canada and the United States. The company offers Rapid Diagnostic Tests for human immunodeficiency virus?½ w/p24Ab, tuberculosis-XT, malaria, hepatitis, syphilis, typhoid, dengue, and other infectious diseases. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.

Receive GNBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GNBT
CUSIPN/A
Phone416-364-2551

Debt

Debt-to-Equity RatioN/A
Current Ratio0.09%
Quick Ratio0.09%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$17.6471 per share
Price / Cash0.17
Book Value($74.78) per share
Price / Book-0.04

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-70,010,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-60.49%

Miscellaneous

Employees12
Outstanding Shares1,070,000

How to Become a New Pot Stock Millionaire

Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

When is Generex Biotechnology's next earnings date?

Generex Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, June, 21st 2018. View Earnings Estimates for Generex Biotechnology.

Who are some of Generex Biotechnology's key competitors?

Who are Generex Biotechnology's key executives?

Generex Biotechnology's management team includes the folowing people:
  • Mr. Joseph Moscato, CEO, Pres & Chairman (Age 54)
  • Mr. Mark Corrao, CFO & Treasurer (Age 59)
  • Mr. Andrew Ro, Chief Investment Officer, Sr. VP of Investments & Director (Age 47)
  • Mr. Mark A. Fletcher Esq., Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Richard D. Purcell, Sr. VP of Research & Drug Devel. (Age 57)

Has Generex Biotechnology been receiving favorable news coverage?

News headlines about GNBT stock have trended positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Generex Biotechnology earned a media sentiment score of 0.27 on Accern's scale. They also gave media stories about the company an impact score of 46.74 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Generex Biotechnology?

Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Generex Biotechnology's stock price today?

One share of GNBT stock can currently be purchased for approximately $3.00.

How big of a company is Generex Biotechnology?

Generex Biotechnology has a market capitalization of $3.20 million. Generex Biotechnology employs 12 workers across the globe.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected]


MarketBeat Community Rating for Generex Biotechnology (GNBT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Generex Biotechnology and other stocks. Vote "Outperform" if you believe GNBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Generex Biotechnology (OTCMKTS:GNBT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/26/2016 forward)

Earnings

Generex Biotechnology (OTCMKTS:GNBT) Earnings History and Estimates Chart

Earnings by Quarter for Generex Biotechnology (OTCMKTS:GNBT)

Generex Biotechnology (OTCMKTS GNBT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/21/2018        
12/14/2017Q1 2018($0.25)ViewN/AView Earnings Details
10/26/2017Q4 2017($11.25)ViewN/AView Earnings Details
6/15/2017Q3 2017$7.05ViewN/AView Earnings Details
3/22/2017Q2 2017($0.35)ViewN/AView Earnings Details
3/7/2014Q2 2014($10.00)ViewN/AView Earnings Details
10/11/2013Q4 2013($10.00)ViewN/AView Earnings Details
10/15/2012Q4 2012($5.00)ViewN/AView Earnings Details
6/11/2012Q3 2012$3.00ViewN/AView Earnings Details
3/12/2012Q2 2012($6.00)ViewN/AView Earnings Details
12/12/2011Q1 2012($9.00)ViewN/AView Earnings Details
10/14/2011Q4 2011($20.00)ViewN/AView Earnings Details
6/9/2008Q3 2008($60.00)($90.00)ViewN/AView Earnings Details
3/11/2008Q2 2008($60.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Generex Biotechnology (OTCMKTS:GNBT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Generex Biotechnology (OTCMKTS GNBT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.20%
Insider Trading History for Generex Biotechnology (OTCMKTS:GNBT)

Generex Biotechnology (OTCMKTS GNBT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Generex Biotechnology (OTCMKTS GNBT) News Headlines

Source:
DateHeadline
Generex CEO Provides 2017 Year-End Summary to StakeholdersGenerex CEO Provides 2017 Year-End Summary to Stakeholders
finance.yahoo.com - January 4 at 9:21 AM
Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions StrategyGenerex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy
finance.yahoo.com - January 3 at 5:30 PM
Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018
finance.yahoo.com - January 3 at 5:30 PM
Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien PharmaceuticalsGenerex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals
finance.yahoo.com - January 2 at 9:20 AM
Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic PlansGenerex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans
finance.yahoo.com - December 18 at 9:35 AM
Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in ChinaGenerex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China
finance.yahoo.com - December 7 at 5:54 PM
Generex Announces Upgrade to OTCQB® Venture MarketGenerex Announces Upgrade to OTCQB® Venture Market
finance.yahoo.com - November 30 at 9:31 AM
Generex Announces Results of Annual Stockholders’ MeetingGenerex Announces Results of Annual Stockholders’ Meeting
finance.yahoo.com - November 27 at 5:39 PM
Generex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® in ChileGenerex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® in Chile
finance.yahoo.com - October 12 at 7:59 PM
Generex Announces New Clinical Trial of Hema Diagnostic Systems’ Rapid 1-2-3® Tuberculosis Point-of-Care TestsGenerex Announces New Clinical Trial of Hema Diagnostic Systems’ Rapid 1-2-3® Tuberculosis Point-of-Care Tests
finance.yahoo.com - September 20 at 3:53 PM
Generex Announces Order For Hema Diagnostic Systems Rapid 1-2-3® Hema HIV EXPRESS® In ChileGenerex Announces Order For Hema Diagnostic Systems' Rapid 1-2-3® Hema HIV EXPRESS® In Chile
www.thestreet.com - September 12 at 7:59 PM
Generex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in ChileGenerex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in Chile
finance.yahoo.com - September 12 at 7:59 PM
Generex Provides Summary of Ii-Key Hybrid Vaccine PlatformGenerex Provides Summary of Ii-Key Hybrid Vaccine Platform
finance.yahoo.com - August 7 at 6:52 PM
Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast CancerGenerex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
finance.yahoo.com - July 31 at 6:44 PM
Generex Biotechnology Corporation (GNBT)Generex Biotechnology Corporation (GNBT)
finance.yahoo.com - July 9 at 11:13 PM
Generex Announces Reverse Stock Split - Business Wire (press release)Generex Announces Reverse Stock Split - Business Wire (press release)
www.businesswire.com - March 16 at 11:44 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and ExhibGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhib
biz.yahoo.com - March 6 at 5:05 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Other Events, FinGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Other Events, Fin
biz.yahoo.com - February 16 at 5:24 PM
Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through "WHO Procurement"Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through "WHO Procurement"
us.rd.yahoo.com - January 25 at 9:48 PM
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology CorporationYutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation
us.rd.yahoo.com - January 25 at 9:48 PM
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation - PR Newswire (press release)Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation - PR Newswire (press release)
www.prnewswire.com - January 25 at 4:47 PM
ADDING MULTIMEDIA Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors - Business Wire (press release)ADDING MULTIMEDIA Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors - Business Wire (press release)
www.businesswire.com - January 25 at 4:47 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K/A, Financial Statements and ExhibitsGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - January 25 at 4:47 PM
Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through ... - Baystreet.caHema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through ... - Baystreet.ca
www.baystreet.ca - January 24 at 6:11 PM
Generex Announces Deal to Acquire Controlling Equity Interest in ... - Business Wire (press release)Generex Announces Deal to Acquire Controlling Equity Interest in ... - Business Wire (press release)
www.businesswire.com - January 24 at 6:11 PM
Generex Announces Closing of Acquisition of Controlling Equity ... - Business Wire (press release)Generex Announces Closing of Acquisition of Controlling Equity ... - Business Wire (press release)
www.businesswire.com - January 24 at 6:11 PM
Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation - PR Newswire (press release)Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation - PR Newswire (press release)
www.prnewswire.com - January 24 at 6:11 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - January 20 at 6:47 PM

SEC Filings

Generex Biotechnology (OTCMKTS:GNBT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Generex Biotechnology (OTCMKTS:GNBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Generex Biotechnology (OTCMKTS GNBT) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.